What Blood Test Should Be Done for Cancer Detection

A blood test for cancer detection today typically involves a combination of a complete blood count (CBC), a comprehensive metabolic panel (CMP), and specific tumor marker assays, with liquid biopsy emerging as a powerful non-invasive screening tool. These tests help identify abnormal cell activity, organ dysfunction, or circulating tumor DNA (ctDNA) that may indicate malignancy. At anylabtests.com, we provide direct-access lab panels designed for early cancer risk assessment, empowering you to take charge of your health with accurate, physician-reviewed results.

Understanding Blood Tests for Cancer Screening

Why Blood Tests Matter today

Cancer remains a leading cause of death in the US, but early detection dramatically improves outcomes. Blood tests can reveal subtle changes in cellular health, inflammation markers, and organ-specific enzymes months before symptoms appear. Today, advancements in liquid biopsy technology allow for multi-cancer early detection (MCED) from a single blood draw, analyzing over 50 cancer-related genetic signals. These tests complement traditional imaging and biopsies, offering a low-risk, repeatable monitoring option.

Primary Blood Test Panels for Cancer

• Complete Blood Count (CBC): Detects anemia, infection, and abnormal white or red cell counts common in leukemia, lymphoma, and bone marrow disorders.
• Comprehensive Metabolic Panel (CMP): Assesses liver and kidney function, calcium levels, and proteins that may indicate metastasis or organ involvement.
• Tumor Markers: Specific proteins like PSA (prostate), CA-125 (ovarian), CA 19-9 (pancreatic), CEA (colorectal), and AFP (liver) help monitor treatment response or recurrence.
• Liquid Biopsy (ctDNA): Detects genetic mutations from tumor cells circulating in blood, enabling early detection of multiple cancers including lung, breast, colorectal, and pancreatic.
• Inflammatory Markers: High-sensitivity CRP, ferritin, and LDH levels can signal systemic inflammation associated with certain cancers.

Choosing the Right Test Based on Risk Factors

Age and Family History

For individuals over 50 with a family history of cancer, the standard recommendation includes a CBC, CMP, and a liquid biopsy panel. Those with specific hereditary syndromes (e.g., BRCA, Lynch) may require more targeted tumor marker testing. Today, guidelines from the American Cancer Society emphasize starting multi-cancer screening at age 45 for average-risk adults.

Symptoms and Suspicion

If you experience unexplained weight loss, persistent fatigue, lumps, or changes in bowel/bladder habits, a broader workup is essential. A panel combining CBC, CMP, LDH, and a liquid biopsy can narrow the diagnostic pathway. For example, elevated CA 19-9 with jaundice may prompt pancreatic imaging, while high PSA with urinary symptoms indicates prostate evaluation.

Interpreting Your Results

What Abnormal Levels Mean

No single blood test can definitively diagnose cancer. Abnormal results require follow-up with imaging, biopsy, or repeat testing. For instance, a high white blood cell count may indicate infection or leukemia, while elevated liver enzymes could point to metastasis. Liquid biopsy results showing ctDNA mutations (e.g., TP53, KRAS) warrant immediate oncologic consultation. Always discuss results with your healthcare provider for a comprehensive evaluation.

Frequency of Testing

For high-risk individuals, annual screening with a CBC, CMP, and tumor markers is advisable. Post-treatment cancer survivors often test every 3–6 months. Liquid biopsy is increasingly used for surveillance, detecting recurrence earlier than conventional imaging. Today, many labs offer at-home collection kits for convenience, though we recommend in-clinic draws for accuracy.

Take the first step toward proactive cancer screening. Order our comprehensive Cancer Screening Panel at anylabtests.com today—no doctor visit required, with results reviewed by our clinical team. Early detection saves lives, and your health journey starts with a simple blood draw.